opc-167832
Small moleculeexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2018 (NCT03678688)
Timeline
Indications
Mechanism of action
- Mycobacterium tuberculosisINHIBITOR
Mycobacterium tuberculosis inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05971602 | Phase 2 | Jul 26, 2023 | Bill and Melinda Gates Foundation, Global Alliance for TB Drug Development, Janssen Pharmaceutica NV, Otsuka |
| NCT05221502 | Phase 2 | Apr 12, 2022 | Bill and Melinda Gates Foundation, Otsuka |
| NCT03678688 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2018 | Bill and Melinda Gates Foundation, Otsuka, TASK Applied Science, University of Cape Town |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 3 | 1 | 1 | 2018 |
| Otsuka | For profit | 3 | 2 | 1 | 2018 |
| Global Alliance for TB Drug Development | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2023 |
| TASK Applied Science | For profit | 1 | 0 | 1 | 2018 |
| University of Cape Town | Academic/Hospital | 1 | 0 | 1 | 2018 |
6 organizations
Page 1 / 1